Bausch Health Companies Inc. or Evotec SE: Who Manages SG&A Costs Better?

Bausch Health vs. Evotec: A Decade of SG&A Management

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Bausch Health Companies Inc. and Evotec SE have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Bausch Health's SG&A expenses have consistently been higher, averaging around $2.57 billion annually. In contrast, Evotec SE has maintained a leaner structure, with average annual expenses of approximately $74 million.

Key Insights

Bausch Health's SG&A expenses peaked in 2023, reaching nearly $2.92 billion, a 44% increase from 2014. Meanwhile, Evotec SE's expenses grew by 843% over the same period, reflecting its strategic expansion. Despite the disparity in absolute numbers, Evotec's growth rate in SG&A expenses suggests a dynamic scaling strategy. This analysis highlights the importance of balancing cost management with growth ambitions in the pharmaceutical sector.